Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Prescriptions*; Central Nervous System Stimulants/*therapeutic use; Geography ; Humans ; United States ; United States Food and Drug Administration

Background: Stimulants are considered the first-line treatment for Attention Deficit Hyperactivity Disorder (ADHD) in the US and they are used in other indications. Stimulants are also diverted for non-medical purposes. Ethnic and regional differences in ADHD diagnosis and in stimulant use have been identified in earlier research. The objectives of this report were to examine the pharmacoepidemiological pattern of these controlled substances over the past decade and to conduct a regional analysis.
Methods: Data (drug weights) reported to the US Drug Enforcement Administration's Automation of Reports and Consolidated Orders System for four stimulants (amphetamine, methylphenidate, lisdexamfetamine, and methamphetamine) were obtained from 2006 to 2016 for Unites States/Territories. Correlations between state level use (mg/person) and Hispanic population were completed.
Results: Amphetamine use increased 2.5 fold from 2006 to 2016 (7.9 to 20.0 tons). Methylphenidate use, at 16.5 tons in 2006, peaked in 2012 (19.4 tons) and subsequently showed a modest decline (18.6 tons in 2016). The consumption per municipality significantly increased 7.6% for amphetamine and 5.5% for lisdexamfetamine but decreased 2.7% for methylphenidate (all p < .0005) from 2015 to 2016. Pronounced regional differences were also observed. Lisdexamfetamine use in 2016 was over thirty-fold higher in the Southern US (43.8 mg/person) versus the Territories (1.4 mg/person). Amphetamine use was about one-third lower in the West (48.1 mg/person) relative to the Northeastern (75.4 mg/person, p < .05) or the Midwestern (69.9 mg/person, p ≤ .005) states. States with larger Hispanic populations had significantly lower methylphenidate (r(49) = -0.63), lisdexamfetamine (B, r(49) = -0.49), and amphetamine (r(49) = -0.43) use.
Conclusions: Total stimulant usage doubled in the last decade. There were dynamic changes but also regional disparities in the use of stimulant medications. Future research is needed to better understand the reasons for the sizable regional and ethnic variations in use of these controlled substances.
Competing Interests: The authors have declared that no competing interests exist.

Pediatrics. 2018 Mar;141(3):. (PMID: 29483202)
MMWR Morb Mortal Wkly Rep. 2018 Mar 30;67(12):349-358. (PMID: 29596405)
MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):66-70. (PMID: 29346342)
Health Aff (Millwood). 2016 Jul 1;35(7):1266-70. (PMID: 27385243)
Pediatrics. 2012 Jul;130(1):23-31. (PMID: 22711728)
JAMA Psychiatry. 2016 Sep 1;73(9):992-3. (PMID: 27331629)
Health Policy. 2010 Sep;97(1):71-8. (PMID: 20382439)
BMC Pediatr. 2017 Dec 29;17(1):218. (PMID: 29284437)
Cochrane Database Syst Rev. 2016 Feb 04;2:CD009996. (PMID: 26844979)
MMWR Morb Mortal Wkly Rep. 2016 May 06;65(17):443-50. (PMID: 27149047)
Health Aff (Millwood). 2007 Mar-Apr;26(2):450-7. (PMID: 17339673)
J Pediatr Pharmacol Ther. 2017 Nov-Dec;22(6):423-429. (PMID: 29290742)
Can J Psychiatry. 2015 Jul;60(7):324-8. (PMID: 26175391)
J Child Adolesc Psychopharmacol. 2014 Aug;24(6):302-10. (PMID: 24956171)
Nicotine Tob Res. 2012 Feb;14(2):191-9. (PMID: 22039071)
JAMA Pediatr. 2017 Feb 1;171(2):181-189. (PMID: 28027344)
Pharmacol Biochem Behav. 2011 May;98(3):432-9. (PMID: 21334365)
J Am Acad Child Adolesc Psychiatry. 2014 Jan;53(1):34-46.e2. (PMID: 24342384)
Pediatrics. 2011 Nov;128(5):1007-22. (PMID: 22003063)
J Nerv Ment Dis. 2012 Jun;200(6):486-8. (PMID: 22652611)
PLoS Med. 2012;9(3):e1001190. (PMID: 22427747)
BMJ. 2010 Mar 26;340:c547. (PMID: 20348183)
Pediatrics. 2009 May;123(5):1273-9. (PMID: 19403491)
Am J Prev Med. 2018 May;54(5):652-660. (PMID: 29551331)
J Child Adolesc Psychopharmacol. 2001 Spring;11(1):15-24. (PMID: 11322741)
Int J Drug Policy. 2016 Sep;35:7-15. (PMID: 27260863)
J Psychoactive Drugs. 2017 Jan-Mar;49(1):22-30. (PMID: 27918861)
Pediatrics. 2016 Sep;138(3):. (PMID: 27553219)
J Child Psychol Psychiatry. 2014 May;55(5):436-45. (PMID: 24274762)
Acad Pediatr. 2017 May - Jun;17(4):349-355. (PMID: 28477799)
Clin Neuropsychol. 2011 Nov;25(8):1415-28. (PMID: 22084858)
Soc Sci Med. 2014 Dec;122:31-43. (PMID: 25441315)
J Clin Psychiatry. 2017 Jul;78(7):e744-e781. (PMID: 28686819)
Prev Chronic Dis. 2013;10:E09. (PMID: 23347704)
Psychiatr Serv. 2018 Mar 1;69(3):322-331. (PMID: 29191137)
Evid Based Med. 2017 Aug;22(4):143-147. (PMID: 28705922)
Am J Med Genet B Neuropsychiatr Genet. 2015 Sep;168(6):406-413. (PMID: 26129777)
Cochrane Database Syst Rev. 2015 Nov 25;(11):CD009885. (PMID: 26599576)
J Clin Child Adolesc Psychol. 2018 Mar-Apr;47(2):199-212. (PMID: 29363986)
JAMA. 2018 Mar 13;319(10):1024-1039. (PMID: 29536101)
Arch Clin Neuropsychol. 2007 Jun;22(5):577-88. (PMID: 17507198)
Atten Defic Hyperact Disord. 2012 Sep;4(3):101-14. (PMID: 22773377)
Annu Rev Clin Psychol. 2018 May 7;14:291-316. (PMID: 29220204)
Pediatrics. 2018 Jan;141(1):. (PMID: 29255083)
Dtsch Arztebl Int. 2017 Mar 3;114(9):141-148. (PMID: 28351466)
J Child Adolesc Psychopharmacol. 2017 Oct;27(8):731-734. (PMID: 28328236)
J Atten Disord. 2016 Jun;20(6):471-7. (PMID: 26486603)
Clin Toxicol (Phila). 2015 Jun;53(5):477-85. (PMID: 25832473)
Arch Gen Psychiatry. 2005 Jun;62(6):593-602. (PMID: 15939837)
J Am Acad Child Adolesc Psychiatry. 2008 Aug;47(8):879-89. (PMID: 18596555)
Eur Neuropsychopharmacol. 2017 May;27(5):484-493. (PMID: 28336088)
J Stud Alcohol Drugs. 2016 Jul;77(4):556-65. (PMID: 27340958)
MMWR Morb Mortal Wkly Rep. 2010 Nov 12;59(44):1439-43. (PMID: 21063274)
Ann N Y Acad Sci. 2010 Feb;1187:316-40. (PMID: 20201860)
Psychiatr Serv. 2015 Oct;66(10):1074-82. (PMID: 26030315)
J Sch Health. 2005 Sep;75(7):248-54. (PMID: 16102087)
Int J Health Policy Manag. 2017 Oct 16;7(2):98-100. (PMID: 29524933)
Public Health Rep. 2017 Nov/Dec;132(6):654-659. (PMID: 29072963)
J Health Econ. 2011 Mar;30(2):355-72. (PMID: 21345506)
JAMA. 2002 Oct 9;288(14):1740-8. (PMID: 12365958)
J Am Acad Child Adolesc Psychiatry. 1999 Jul;38(7):797-804. (PMID: 10405496)
J Contemp Health Law Policy. 2003 Spring;19(2):495-520. (PMID: 14748255)
Can J Psychiatry. 2012 Feb;57(2):93-101. (PMID: 22340149)
Psychol Assess. 2017 Dec;29(12):1447-1457. (PMID: 29227126)
Neurotoxicol Teratol. 2014 Jul-Aug;44:30-45. (PMID: 24846602)
Am J Psychiatry. 2012 Mar;169(3):264-72. (PMID: 22294258)
Pediatrics. 2014 Nov;134(5):1013-23. (PMID: 25287462)
BMC Pharmacol. 2006 Mar 03;6:6. (PMID: 16515684)
Biochem Pharmacol. 2013 Jul 15;86(2):309-16. (PMID: 23623751)
BMC Psychiatry. 2017 Jan 19;17(1):32. (PMID: 28103833)
Psychol Assess. 2010 Jun;22(2):325-35. (PMID: 20528060)
Am J Psychiatry. 2006 Apr;163(4):716-23. (PMID: 16585449)

T32 ES007060 United States ES NIEHS NIH HHS

0 (Central Nervous System Stimulants)

Date Created: 20181129 Date Completed: 20190408 Latest Revision: 20240404

20240404

PMC6261411

10.1371/journal.pone.0206100

30485268